Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer.
about
A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancerExpert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UKSkin problems and EGFR-tyrosine kinase inhibitorEfficacy and safety of antitumor agents plus radiotherapy compared with radiotherapy alone for brain metastases from lung cancer.Development of the rat model of lapatinib-induced diarrhoea.A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neckManagement of Common Toxicities in Metastatic NSCLC Related to Anti-Lung Cancer Therapies with EGFR-TKIs.Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond ProgressionManagement of egfr tki-induced dermatologic adverse events.A personalized approach to treatment: use of EGFR tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer in Canada.A systematic review and meta-analysis of the risk of diarrhea associated with vandetanib treatment in carcinoma patients.Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management.Optimal strength and timing of steroids in the management of erlotinib-related skin toxicities in a post-marketing surveillance study (POLARSTAR) of 9909 non-small-cell lung cancer patientsDaily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel.Algorithm for dermocosmetic use in the management of cutaneous side-effects associated with targeted therapy in oncology.Diarrhea associated with afatinib: an oral ErbB family blocker.Tyrosine kinase inhibitors: their on-target toxicities as potential indicators of efficacy.Targeting the epidermal growth factor receptor in solid tumors: focus on safety.Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel.Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.The safety of afatinib for the treatment of non-small cell lung cancer.Erlotinib-associated rash in patients with EGFR mutation-positive non-small-cell lung cancer treated in the EURTAC trial.Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities."I Lost My Image, the Image Others Know Me By": Findings From a Hermeneutic Phenomenological Study of Patients Living With Treatment-Induced Cutaneous Toxicities.Role of Systemic Antibiotics in Preventing Epidermal Growth Factor Receptor: Tyrosine Kinase Inhibitors-induced Skin ToxicitiesPharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.Preventive effect of kampo medicine (hangeshashin-to, TJ-14) plus minocycline against afatinib-induced diarrhea and skin rash in patients with non-small cell lung cancer.Recent advances in the management of non-small cell lung cancer.Somatic mutations in salivary duct carcinoma and potential therapeutic targets.Turning EGFR mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors.Management Strategies for Adverse Events Associated With EGFR TKIs in Non-Small Cell Lung Cancer.Pharmacokinetic properties of two erlotinib 150 mg formulations with a genetic effect evaluation in healthy Korean subjects.Assessment of pulmonary 18F-FDG-PET uptake and cytokine profiles in non-small cell lung cancer patients treated with radiotherapy and erlotinib.
P2860
Q24626194-7C340F00-406D-4C70-BA2B-92C536A0D36CQ26799390-648CCAF8-4D3D-4568-BDFA-74D1D98D15DCQ28069454-F2AA59E5-1200-4DCA-ADFA-A21E4E1BD3D7Q33599135-1A784A9D-0CBE-49B3-A590-4EFE85801203Q33999288-4104E4B9-A855-4258-8221-FEC264F31ABBQ34083131-E9626FDC-29B5-4551-A8BD-96D4E312F62EQ34192836-C98847DA-08BB-4D52-A79C-C321D8C9B3C5Q34637855-3ADB0767-9913-436A-B335-198988E1708CQ34650994-A0967ED6-BA7B-42AA-8B42-55E1AAF5FC4CQ35444952-6958BDAD-8F7D-46FD-99CF-43C6DAD20810Q35872687-CF9DA0E2-6C15-4255-AB60-8E57FB2B8829Q36068707-C4895844-1BE8-4F63-94E8-F083A1ADFF63Q36246406-64D78AD0-853F-4EC8-A255-7A8C4A971ACEQ36778198-81FB3C9F-181B-4A67-8235-47607B9CE375Q37390753-B2F4E14F-03C6-4197-B74D-E1C4E28AAE39Q37442683-08ACA6CE-8A01-4269-84A0-02A6A78FB79BQ38090739-2FCFBC81-CB79-4035-8758-A37EF8047F28Q38101885-6B81E581-66F3-4B0B-B38A-99DCB71073B9Q38200654-2A8B3942-FAC8-4237-8912-4C860FE7C5BFQ38252486-DA978DF9-A5CB-4E14-AA76-EBCBE2958892Q38575289-B013DBAF-61AE-4DBC-980B-5ED963FA36FDQ38955468-EBC744D9-7527-4D31-A525-43DECB42DBBAQ39040330-6F26515E-F124-463F-9147-E98F344F1FE6Q39278689-1DD9727E-7E34-4185-9C88-B656FEFFA2A2Q39849391-B7EB98FB-5F15-468E-A339-19A19E30BF15Q41835826-DE4296FC-52AC-4F0D-87C6-1CE5BDEEA36EQ45662172-0044CFE5-1F90-4935-A8C9-F0172EA5B667Q47102325-1A01CDA5-AF06-4D69-BA6D-DC109B059051Q47105316-CFFF6F37-A154-4622-8CD1-D08871D984C7Q47133482-42155CF9-2401-48DF-B54D-FB33017A6DA0Q49300205-DF029559-3874-4E80-A302-FC63F0C9628AQ54166640-C2F0DE87-F84A-456E-A5B2-6EFB54BE7358Q55070162-269F5A3F-2B3C-4FD2-97F7-19E46170CE46Q55299188-655B57BE-0CFC-43F0-B9D8-83DB42F3EDC1
P2860
Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Managing treatment-related adv ...... ed non-small-cell lung cancer.
@ast
Managing treatment-related adv ...... ed non-small-cell lung cancer.
@en
type
label
Managing treatment-related adv ...... ed non-small-cell lung cancer.
@ast
Managing treatment-related adv ...... ed non-small-cell lung cancer.
@en
prefLabel
Managing treatment-related adv ...... ed non-small-cell lung cancer.
@ast
Managing treatment-related adv ...... ed non-small-cell lung cancer.
@en
P2860
P356
P1433
P1476
Managing treatment-related adv ...... ed non-small-cell lung cancer.
@en
P2093
P2860
P304
P356
10.3747/CO.V18I3.877
P577
2011-06-01T00:00:00Z